<?xml version="1.0" ?>
<GlossaryTerm id="CDR0000641978">
  <TermName>multitargeted receptor tyrosine kinase inhibitor ABT-869</TermName>
  <TermPronunciation>(MUL-tee-TAR-geh-ted reh-SEP-ter TY-ruh-seen KY-nays in-HIH-bih-ter …)</TermPronunciation>
  <TermDefinition>
    <DefinitionText>A substance being studied in the treatment of several types of cancer. Multitargeted receptor tyrosine kinase inhibitor ABT-869 blocks the action of several growth factors. It may also block the growth of new blood vessels that tumors need to grow and may cause cancer cells to die. It is a type of receptor tyrosine kinase inhibitor and a type of angiogensis inhibitor. Also called ABT-869.</DefinitionText>
    <Dictionary>Cancer.gov</Dictionary>
    <Audience>Patient</Audience>
  </TermDefinition>
  <MediaLink ref="CDR0000722912" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;multitargeted receptor tyrosine kinase inhibitor ABT-869&quot;" language="en" id="_3"/>
  <MediaLink ref="CDR0000722911" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;inhibidor multidirigido a receptores tirosina–cinasas ABT-869&quot;" language="es" id="_4"/>
  <SpanishTermName>inhibidor multidirigido a receptores tirosina–cinasas ABT-869</SpanishTermName>
  <SpanishTermDefinition>
    <DefinitionText>Sustancia en estudio para el tratamiento de varios tipos de cáncer. El inhibidor multidirigido a receptores tirosina–cinasas ABT-869 impide la acción de diferentes  factores de crecimiento. Es posible que también impida la formación de los vasos sanguíneos nuevos que los tumores necesitan para crecer y quizás destruya células cancerosas. Es un tipo de inhibidor de receptores tirosina–cinasas y de inhibidor de la angiogénesis. También se llama ABT-869 e inhibidor multiselectivo de receptores tirosina–cinasas ABT-869.</DefinitionText>
    <Dictionary>Cancer.gov</Dictionary>
    <Audience>Patient</Audience>
  </SpanishTermDefinition>
  <DateFirstPublished>2009-07-21</DateFirstPublished>
</GlossaryTerm>
